Margaret Norsworthy, APRN
Family · Murray, KYNPI 1114301801
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,725 of the $22,415 with a category attached, or 61.2%. AbbVie accounts for 75.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $18,210 and has fallen 96.5% since, to $644 in 2025. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $47.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Biohaven Pharmaceuticals, Inc.$594
- Livanova USA, Inc.$561
- Eisai Inc.$388
- Novartis$385
- Biohaven Pharmaceutical Holding Company Ltd.$333
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$13,72561%
- Travel & lodging$1,0705%
- Food & beverage$7,46233%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $16,923 |
| Biohaven Pharmaceuticals, Inc. | 57 | $594 |
| Livanova USA, Inc. | 2 | $561 |
| Eisai Inc. | 22 | $388 |
| Novartis | 31 | $385 |
| Biohaven Pharmaceutical Holding Company Ltd. | 28 | $333 |
| Biogen | 23 | $326 |
| Amgen | 20 | $311 |
| Avanir Pharmaceuticals, Inc. | 11 | $252 |
| Lilly USA, LLC | 14 | $211 |
| Acadia Pharmaceuticals Inc | 12 | $208 |
| Jazz Pharmaceuticals Inc. | 8 | $201 |
| Neurocrine Biosciences, Inc. | 9 | $172 |
| Mallinckrodt Hospital Products Inc. | 8 | $144 |
| CSL Behring | 6 | $138 |
| Sanofi | 8 | $135 |
| Supernus Pharmaceuticals, Inc. | 7 | $118 |
| Lundbeck LLC | 7 | $114 |
| Pfizer | 6 | $109 |
| EMD Serono, Inc. | 5 | $99 |
| Teva Pharmaceuticals USA, Inc. | 3 | $96 |
| Johnson & Johnson | 5 | $88 |
| Amneal Pharmaceuticals LLC | 5 | $81 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Tanabe Pharma America, Inc. | 3 | $48 |
| Bristol Myers Squibb | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Adamas Pharmaceuticals, Inc. | 2 | $35 |
| AstraZeneca | 1 | $29 |
| Aquestive Therapeutics, Inc. | 1 | $23 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Neurelis, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$12,416
- QULIPTA$2,250
- VNS Therapy$561
How this compares
$22,415 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 35 | $47,869 |
| UbrelvyUbrogepant | 41 | $47,342 |
| QuliptaAtogepant | 15 | $18,202 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,030 |
| Emgality PenGalcanezumab-Gnlm | 16 | $16,510 |
| AptiomEslicarbazepine Acetate | 13 | $16,252 |
| BotoxOnabotulinumtoxina | 11 | $14,003 |
| Levetiracetam | 126 | $3,124 |
| Propranolol Hcl ErPropranolol Hcl | 91 | $2,832 |
| Gabapentin | 98 | $1,896 |
| Entacapone | 19 | $1,390 |
| Carbamazepine | 19 | $1,364 |
| Memantine Hcl | 65 | $1,020 |
| Oxcarbazepine | 25 | $868 |
| Phenytoin Sodium Extended | 20 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $16,923 | $79,54767 claims |
| PfizerNurtec Odt | $109 | $47,86935 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $252 | $17,03011 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $20 | $16,25213 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $81 | $51711 claims |
| Upsher-smith Laboratories LLCTopiramate | $22 | $19124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Murray
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
- Carrie Parrish NyekanBowling Green$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.